Posts

Cannabidiol A Race To Relief

Authors: Nishi Whiteley and Ethan Russo, MD Published in HerbalGram 2020 Introduction Few chemical compounds have enjoyed such a rapid ascent to market acceptance and consumer popularity as CBD. According to BDS Analytics, the US hemp-derived CBD market is projected to grow to $20 billion by 2024.1 CBD was the top-selling herbal dietary supplement in…

Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome

Authors: Gil Bar-Sela, Cohen Idan, Salvatore Campisi-Pinto, Gil M Lewitus Published in Cancers August 2020 Abstract Cannabis or its derivatives are widely used by patients with cancer to help with cancer symptoms and treatment side effects. However, cannabis has potent immunomodulatory properties. To determine if cannabis consumption during immunotherapy affects therapy outcomes, we conducted a…

Cannflavins – From plant to patient: A scoping review

Authors: Simon Erridge, Nagina Mangal, Oliver Salazar, Barbara Pacchetti, Mikael H.Sodergren Published in Fitoterapia October 2020 Abstract Introduction Cannflavins are a group of prenylflavonoids derived from Cannabis sativa L.. Cannflavin A (CFL-A), B (CFL-B) and C (CFL-C) have been heralded for their anti-inflammatory properties in pre-clinical evaluations. This scoping review aims to synthesise the evidence…

Cannabis in palliative medicine: improving care and reducing opioid-related morbidity.

Authors: Gregory T. Carter, Aaron M. Flanagan, Mitchell Earleywine, Donald I. Abrams, et al
American Journal of Hospice and Palliative Medicine, August 2011

Unlike hospice, long-term drug safety is an important issue in palliative medicine. Opioids may produce significant morbidity. Cannabis is a safer alternative with broad applicability for palliative care. Yet the Drug Enforcement Agency (DEA) classifies cannabis as Schedule I…